Suzanne Gagnon

ORCID: 0009-0007-3607-5425
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Biomedical Ethics and Regulation
  • Cancer, Hypoxia, and Metabolism
  • Travel-related health issues
  • Cancer Research and Treatments
  • Dental Anxiety and Anesthesia Techniques
  • Hepatitis Viruses Studies and Epidemiology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Ethics in Clinical Research
  • Pancreatic and Hepatic Oncology Research
  • Cancer-related gene regulation
  • Medical History and Innovations
  • Hemoglobinopathies and Related Disorders
  • Erythropoietin and Anemia Treatment
  • Iron Metabolism and Disorders
  • Tuberculosis Research and Epidemiology
  • Pharmacological Effects and Toxicity Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Colorectal Cancer Treatments and Studies
  • HIV/AIDS drug development and treatment
  • Anesthesia and Sedative Agents
  • Cancer Treatment and Pharmacology
  • Pneumonia and Respiratory Infections
  • Infectious Diseases and Tuberculosis
  • Entomological Studies and Ecology
  • Statistical Methods in Clinical Trials

Gannon University
2023

UNM Comprehensive Cancer Center
2021

New Mexico Cancer Center
2021

University of New Mexico
2021

Institut National de Santé Publique du Québec
2006-2014

Pinnacle Clinical Research
2011-2014

Institut National de Santé Publique
2006

Cornell University
2000-2001

University of Arizona
2000-2001

New York Hospital Queens
2001

Preliminary reports suggest that patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia may benefit from addition of corticosteroid treatment to antibiotic therapy.

10.1056/nejm199011223232103 article EN New England Journal of Medicine 1990-11-22

10.14219/jada.archive.2001.0152 article EN The Journal of the American Dental Association 2001-02-01

10.14219/jada.archive.2000.0237 article EN The Journal of the American Dental Association 2000-05-01

Visiting friends and relatives (VFRs), especially young VFRs, are increasingly recognized in the industrialized world as a high-risk group of travelers.We performed descriptive, cross-sectional design study cases malaria, hepatitis A, typhoid reported to Quebec registry notifiable diseases between January 2004 December 2007, occurring VFRs non-VFRs travelers.VFRs account for 52.9% malaria cases, 56.9% A 94.4% travelers. Almost all (91.6%) among were acquired Africa, particularly sub-Saharan...

10.1111/j.1708-8305.2011.00556.x article EN Journal of Travel Medicine 2011-10-12

To study the effect of rifampin (INN, rifampicin), a potent inducer cytochrome P450, on steady-state pharmacokinetics delavirdine.Twelve patients who were positive for human immunodeficiency virus, with CD4 counts ranging from 110 to 483/mm3, randomized two groups and studied in parallel. Both control group (n = 5) 7) received 400 mg delavirdine mesylate every 8 hours 30 days; subjects took 600 once-daily dose days 16 through 30. Harvested plasma serial blood samples collected after dosing...

10.1016/s0009-9236(97)90134-x article EN Clinical Pharmacology & Therapeutics 1997-05-01

The ability to predict drug deposition of inhaled drugs used in cystic fibrosis (CF) is important if there a need target specific doses the lungs individual patients. gold standard measuring pulmonary quantification an aerosolized radiolabel either mixed with solution or tagged directly compound interest. Accuracy could be assured agreement between amount radioactivity before and after administration. Before administration, concentrated well nebulizer, whereas it distributed throughout...

10.1089/jam.2000.13.169 article EN Journal of Aerosol Medicine 2000-01-01

e16311 Background: Previously, elraglusib (9-ING-41), an inhibitor of Glycogen Synthase Kinase-3 (GSK-3), was shown to potentiate the anticancer effects chemotherapeutic drugs in preclinical models cancer. The combination and gemcitabine/nab-paclitaxel (GnP) is currently being investigated a randomized, open-label 1801 phase 2 study as first-line therapy for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Chemotherapy-induced neutropenia common dose-limiting toxicity...

10.1200/jco.2024.42.16_suppl.e16311 article EN Journal of Clinical Oncology 2024-06-01

Study Objectives . To characterize patient sociodemographics and health, describe vancomycin treatment parameters clinician‐rated outcomes, determine costs associated with including preparation administration, adverse events, toxicity. Design A prospective study to develop a model for antibiotic (vancomycin). Setting community hospital. Patients One hundred adults active infections. Interventions Mean duration of therapy was 10 days, most patients received 2000 mg/day. Serum concentrations...

10.1002/j.1875-9114.1994.tb02834.x article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 1994-07-08

Analysis of epidemiological data on health problems related to international travel helps put into perspective preventive interventions for travelers. To document the context in Québec, we reviewed surveillance three infectious diseases. The analysis included collected notifiable diseases system hepatitis A, typhoid, and malaria cases reported from 2000 2002. Additional were obtained provincial risk factor database as well regional public departments. More than 40% A which information is...

10.1111/j.1708-8305.2006.00031.x article EN Journal of Travel Medicine 2006-07-01

4127 Background: SBP-101, a polyamine metabolic inhibitor, inhibited growth in 6 human pancreatic ductal adenocarcinoma (PDA) cell lines and 3 murine xenograft tumor models of PDA. SBP-101 monotherapy heavily pre-treated PDA patients (> 2 prior regimens) showed median survival 5.9 months at the optimal dose level. Purpose: To assess PK, safety efficacy combination with gemcitabine (G) nab-paclitaxel (A) previously untreated metastatic Methods: In modified 3+3 escalation scheme,...

10.1200/jco.2021.39.15_suppl.4127 article EN Journal of Clinical Oncology 2021-05-20

Prior to enactment of the final investigational new drug application (IND) safety reporting rule, an attempt was made document effort expended at investigative sites in processing IND reports from sponsors and assess effect these expedited on trial conduct. Investigators were asked (1) prospectively time process (2) retrospectively review a previous 3-month period, documenting resultant actions. In this limited sample, spent median 0.25 hours per report cost US$22. Few said have changed...

10.1177/2168479013520160 article EN cc-by Therapeutic Innovation & Regulatory Science 2014-01-31

To determine whether intravenous indigo carmine provides a visualization advantage compared to saline in the evaluation of ureteral patency randomized, controlled clinical trial.

10.1016/j.urology.2023.11.005 article EN cc-by Urology 2023-12-05

Travel-related shigellosis is not well documented in Canada although it frequently acquired abroad and can cause severe disease.To describe the epidemiology of travel-related cases for Quebec (Canada) to identify high-risk groups travelers.We performed a random sampling 335 (from total 760 cases) reported provincial database reportable diseases from January 1, 2004, December 31, 2007. Each case was analyzed according information available questionnaire. Total number trips by region...

10.1111/jtm.12130 article EN Journal of Travel Medicine 2014-06-03

To continuously improve its assistance to Québec travel health providers, the Advisory Committee on Travel Health conducted an exploratory and descriptive survey of dedicated clinics in (Canada). During autumn 2003, a cross-sectional was carried out among 97 listed Québec. Data were collected using self-administered questionnaire sent by mail. The response rate 94%. More than three quarters are located community centers; others private hospitals. Although 80% outside most densely inhabited...

10.1111/j.1708-8305.2006.00044.x article EN Journal of Travel Medicine 2006-07-01

e16231 Background: SBP-101 (diethyl dihydroxyhomospermine), a polyamine (PA) analogue of spermine, inhibited growth in 6 human PDA cell lines and 3 murine xenograft tumor models. A Phase 1 dose escalation study assessed the safety, tolerability pharmacokinetics (PK) previously treated patients with locally advanced or metastatic PDA. Methods: In modified 3x3 scheme, daily subcutaneous injections were dosed at 0.05, 0.1, 0.2, 0.4 0.8 mg/kg, Monday-Friday for weeks, followed by 5 weeks...

10.1200/jco.2018.36.15_suppl.e16231 article EN Journal of Clinical Oncology 2018-05-20
Coming Soon ...